A pair of research teams are testing nivolumab to determine if the drug can be used to target mesothelioma.
Scientists at the University of Southampton and the University of Leicester are conducting trials at the University of Southampton’s Centre for Cancer Immunology, which will be the UK’s first and only facility dedicated to cancer immunology research.
Mesothelioma, which is caused by asbestos, has seen incidence rates increased almost six-fold (497 percent) in Great Britain.
It is estimated that there were around 2,700 new cases of mesothelioma in the UK in 2013 – more than seven cases diagnosed every day.
Current treatment methods include chemotherapy, radiotherapy or surgery and are mainly aimed at keeping the cancer under control.
[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.